Rein Therapeutics Phase 2 Trial Update for LTI-03 in IPF
Eight patients have been enrolled to date in Rein Therapeutics’ randomized, placebo-controlled Phase 2 RENEW trial of LTI-03 for...
OPTIMAL-PSMA Trial: A Promising New Hope for Prostate Cancer
Initial dosimetry from the randomized Phase 2 OPTIMAL-PSMA study indicates TLX597-Tx delivers higher tumor uptake with low salivary gland...
Syncromune Presents Innovative Sync-T Immunotherapy Approach
In a single-arm Phase 1 study of 15 patients with metastatic prostate cancer, Syncromune’s SYNC-T Therapy SV-102 reported an...
Tempest Unveils Promising Dual-Targeting CAR-T Platform
Interim data from the REDEEM-1 Phase 1/2a study reported earlier this year showed a 100% complete response rate among...
The Process Is the Point: Why One Enterprise Leader Says Pharma Keeps Automating the Wrong Thing
Poonam Rihel Senior Enterprise Leader, R&D Poonam Rihel has watched a decade of digital transformation initiatives in pharma produce...
The 35% Problem: Why Isolate-Based AST Is Systematically Under-Detecting Resistance in Complicated Urinary Tract Infection
The 35% Problem — The Clinical Trial Vanguard The clinician prescribed empirically. The lab report said susceptible. Three weeks...
FDA Real-Time Clinical Trials: Why AI Systems That Update Themselves Are Breaking Clinical Trial Design
FDA's April 2026 real-time clinical trial push exposes a fatal flaw: when AI updates itself mid-study, your protocol is...
Hope for Back Pain: Mesoblast’s Phase 3 Trial Fully Enrolled
Mesoblast has completed enrollment in its 300-patient, sham-controlled Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain...
Coultreon Biopharma Raises $125M for Immunology Pipeline
Coultreon Biopharma closed an oversubscribed $125 million Series A to push its lead oral SIK3 inhibitor, COL-5671, from Phase...
Promising New KRAS Inhibitor Trial Doses Its First Patient
Kestrel Therapeutics dosed the first patient in FALCON, its Phase 1, open-label dose-escalation and expansion study of KST-6051, an...